Clinical Trial

Single-ascending Dose Study of Kylo-12 in Healthy Subjects

Active, Not Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This is a first-in-human, randomized, double-blind, placebo-controlled, single ascending dose study in healthy volunteers. Kylo-12 will be evaluated in approximately 50 subjects to assess safety, tolerability, pharmacokinetics and pharmacodynamic effects.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2025-01-14; most recent amendment 2026-03-12.
Status change: Not Yet Recruiting → Active, Not Recruiting 2025-09-16
Trial Details
NCT Number NCT06783881
Lead Sponsor Kylonova (Xiamen) Biopharma co., LTD.
Conditions Hypertriglyceridemia
Enrollment 50 participants
Start Date 2025-03-12
Primary Completion 2025-12-19 (estimated)
Study Completion 2026-08-30 (estimated)
Updated on ClinicalTrials.gov 2026-03-16